Communications technologies ultimately should be chosen for their appropriateness and effectiveness at executing a given task, not because they are the latest, greatest novelty, no matter how impressive they may seem.
Despite having an impressive roster of high-profile supporters, including AbbVie, BMS, J&J, Novartis and Pfizer, PARP-focused Ribon has called it quits after nearly a decade in business.
Ultracompact CRISPR systems, which are in some cases one-third the size of Cas9, are being designed to be more specific and enable in vivo gene editing in difficult to reach tissues.
While an FDA advisory committee voted overwhelmingly against approving the psychedelic therapy, experts suggest it may still have a chance.
Losses at German drugmaker BioNTech quadrupled in the second quarter from a year earlier, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sales of its COVID-19 vaccine.
As Eli Lilly’s weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk’s Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?